Cibus, Inc. (CBUS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Cibus, Inc. is an agricultural biotechnology company utilizing gene editing (RTDS platform) to develop plant traits for major food crops. The company operates as a "smaller reporting company" and "non-accelerated filer." As of November 10, 2025, there were approximately 54.3 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $615 | $1,667 | $2,582 | $3,050 |
| Net Loss | $(24,303) | $(201,459) | $(100,253) | $(256,909) |
| Net Loss Attributable to Stockholders | $(23,541) | $(179,968) | $(95,799) | $(228,286) |
| Loss Per Share (Basic & Diluted) | $(0.44) | $(7.63) | $(2.21) | $(10.33) |
| Cash and Cash Equivalents | $23,886 | $28,805 | $23,886 | $28,805 |
| Current Liabilities | $20,559 | $19,878 | $20,559 | $19,878 |
| Operating Cash Flow (9M) | $(37,171) | $(44,048) | $(37,171) | $(44,048) |
| Goodwill Impairment (9M) | $20,950 | $181,432 | $20,950 | $181,432 |
Debt and Liquidity: The company holds a significant Royalty Liability to Related Parties of $225.5 million (non-current), which accrues interest expense of approximately $26.1 million for the nine months ended September 30, 2025. Current liabilities include $7.3 million in accrued expenses and $2.7 million in current operating lease obligations.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 63% in Q3 2025 compared to Q3 2024, driven by lower amounts earned from collaboration agreements (specifically Rice and Sustainable Ingredients).
- Reduced Net Loss: The net loss improved significantly (88% reduction in Q3) primarily due to the absence of the $181.4 million goodwill impairment recorded in Q3 2024. A smaller goodwill impairment of $21.0 million was recorded in Q1 2025.
- Cost Reductions: R&D and SG&A expenses decreased by 17% and 31% respectively in Q3 2025, reflecting ongoing restructuring initiatives and workforce reductions.
- Capital Raises: The company raised approximately $46.4 million in net proceeds during the first nine months of 2025 through a January registered direct offering and a June public offering.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. Cash on hand ($23.9 million) is projected to fund operations only into early Q2 2026 without additional financing.
- Strategic Pivot: The company is streamlining operations to focus exclusively on Rice weed management traits and partner-funded sustainable ingredients. Non-core programs are being paused or scaled back.
- Workforce Reduction: A reduction of approximately 34 full-time employees was approved in July 2025 to reduce annual net cash burn to approximately $30 million by 2026.
- Regulatory Progress: Key milestones include USDA-APHIS designations for Canola traits as "not regulated" and regulatory approvals in Ecuador and California for gene-edited Rice field trials.
- Contingencies: The company accrued a $2.6 million litigation liability in Q3 2025 related to an unexpected Ninth Circuit Court of Appeals decision requiring the repayment of insurance proceeds.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "early Q2 2026" liquidity projection and the $2.6 million unexpected litigation liability.
- Royalty Liability: Assess the impact of the $225.5 million related-party royalty liability and its $26M+ annualized interest expense on future cash flows and equity dilution.
- Commercialization Timeline: Confirm the progress of the Rice herbicide tolerance traits, specifically the 2027 Latin America and 2028 U.S. launch targets.
- Restructuring Execution: Monitor the completion of the workforce reduction and the realization of the targeted $30 million annual cash burn by 2026.
- Regulatory Status: Track the finalization of EU New Genomic Techniques (NGT) legislation and UK Precision Bred Organisms (PBO) implementation, which are critical for global market access.